Skip to content

US · LRMR · BIOTECHNOLOGY

Larimar Therapeutics, Inc. (LRMR) intrinsic value and stock valuation

$3.14as of 2026-11-21 · Mkt cap 425.92M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Larimar Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values LRMR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LRMR’s statements →

Larimar Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bala Cynwyd, PA 19004 larimartx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-165.67M
20112025
Free cash flow
-$-113.29M
20112025
Total equity
$78.1M-2.7% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-172.5M-$-90.89M-$-41.76M-$-36.53M-$-50.47M
Net income-$-165.67M-$-80.6M-$-36.95M-$-35.35M-$-50.64M
EPSd-$-2.27M-$-1.32M-$-841.69K-$-1.37M-$-2.95M
Operating cash flow-$-113.2M-$-70.76M-$-33.46M-$-27.57M-$-42.1M
Capital expenditure-$-90K-$-520K-$-160K-$-100K-$-330K
Free cash flow-$-113.29M-$-71.28M-$-33.62M-$-27.67M-$-42.44M
Total assets$145.8M$200.2M$95.9M$126.4M$78.7M
Total debt$4.07M$5.12M$5.55M$5.41M$6M
Net debt-$-81.34M-$-28.1M-$-21.2M-$-21.42M-$-64.09M
Total equity$78.1M$171.8M$81.7M$110.9M$64.4M
Cash and short-term investments$136.9M$183.5M$86.8M$118.4M$70.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$154.2M$73.3M$27.7M$24.3M$38.4M
Selling, general and administrative expenses$18.3M$17.6M$14.1M$12.3M$12.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$172.5M$90.9M$41.8M$36.5M$50.5M
Cost and expenses$172.5M$90.9M$41.8M$36.5M$50.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$350K$320K$310K$320K$330K
Ebitda-$-165.32M-$-80.29M-$-36.64M-$-35.04M-$-50.31M
Operating income-$-172.5M-$-90.89M-$-41.76M-$-36.53M-$-50.47M
Total other income/expenses, net$6.82M$10.3M$4.81M$1.17M-$-170K
Income before tax-$-165.67M-$-80.6M-$-36.95M-$-35.35M-$-50.64M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-165.67M-$-80.6M-$-36.95M-$-35.35M-$-50.64M
Weighted average shares outstanding$73M$61.3M$43.9M$25.8M$17.2M
Weighted average diluted shares outstanding$73M$61.3M$43.9M$25.8M$17.2M
Balance sheet
20252024202320222021
Cash and short-term investments$136.9M$183.5M$86.8M$118.4M$70.1M
Net receivables$750K$1.05M$330K$0.00$210K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$142M$195.3M$90.2M$120.7M$72.2M
Property, plant and equipment, net$2.69M$3.72M$3.76M$3.69M$4.46M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$1.34M$0.00$1.34M
Total non-current assets$3.82M$4.92M$5.76M$5.67M$6.46M
Total assets$145.8M$200.2M$95.9M$126.4M$78.7M
Accounts payable$5.22M$2.42M$1.28M$1.69M$1.66M
Short-term debt$1.1M$1.06M$840K$610K$590K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$64.8M$24.4M$9.51M$10.7M$8.85M
Long-term debt$2.96M$4.06M$4.71M$4.8M$5.41M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.96M$4.06M$4.71M$4.8M$5.41M
Capital lease obligations$2.96M$5.12M$5.55M$5.41M$6M
Total liabilities$67.8M$28.4M$14.2M$15.5M$14.3M
Common stock$80K$60K$40K$40K$20K
Retained earnings-$-434.83M-$-269.16M-$-188.55M-$-151.6M-$-116.25M
Accumulated other comprehensive income (loss)$50K$150K$80K-$-30K$0.00
Total equity$78.1M$171.8M$81.7M$110.9M$64.4M
Total investments$51.4M$150.2M$61.4M$91.6M$1.34M
Total debt$4.07M$5.12M$5.55M$5.41M$6M
Net debt-$-81.34M-$-28.1M-$-21.2M-$-21.42M-$-64.09M
Cash flow statement
20252024202320222021
Net income-$-165.67M-$-80.6M-$-36.95M-$-35.35M-$-50.64M
Depreciation and amortization$350K$320K$310K$320K$330K
Stock-based compensation$7M$8.8M$7.62M$6.62M$5.47M
Change in working capital$47.1M$6.17M-$-2.51M$1.67M$2.75M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.79M$1.14M-$-400K$30K-$-970K
Net cash provided by operating activities-$-113.2M-$-70.76M-$-33.46M-$-27.57M-$-42.1M
Investments in property, plant and equipment-$-90K-$-520K-$-160K-$-100K-$-330K
Acquisitions, net$0.00$0.00$0.00$90K-$-20K
Net cash used for investing activities$100.3M-$-85.39M$33.4M-$-90.96M$24.2M
Common stock issued$65.1M$161.8M$30K$75.3M$19.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$65.1M$161.9M$30K$75.3M$19.9M
Net change in cash$52.2M$5.74M-$-80K-$-43.27M$1.95M
Cash at end of period$86M$33.8M$26.8M$28.2M$71.4M
Operating cash flow-$-113.2M-$-70.76M-$-33.46M-$-27.57M-$-42.1M
Capital expenditure-$-90K-$-520K-$-160K-$-100K-$-330K
Free cash flow-$-113.29M-$-71.28M-$-33.62M-$-27.67M-$-42.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Larimar Therapeutics, Inc.

        Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

        CEO
        Carole S. Ben-Maimon
        Employees
        71
        Beta
        0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Larimar Therapeutics, Inc. (LRMR)?

        InvestorsCraft does not currently publish an intrinsic value for LRMR. How the IC value is calculated.

        Is LRMR undervalued?

        InvestorsCraft does not publish an undervaluation signal for LRMR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.